Protein / target
Type-1 angiotensin II receptor
Protein at a glance
Biological role
Angiotensin type II receptor
Strongest disease association
Renal tubular dysgenesis of genetic origin
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney.
View complete UniProt function annotationHide complete annotation
Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney (PubMed:15611106, PubMed:1567413, PubMed:25913193, PubMed:26420482, PubMed:30639100, PubMed:32079768, PubMed:8987975). The activated receptor in turn couples to G-alpha proteins G(q) (GNAQ, GNA11, GNA14 or GNA15) and thus activates phospholipase C and increases the cytosolic Ca(2+) concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C (PubMed:15611106)
Subcellular location
Domains and Gene Ontology detail (33)Hide
Gene Ontology
- Cmembrane
- Cplasma membrane
- Fangiotensin type I receptor activity
- Fangiotensin type II receptor activity
- Fbradykinin receptor binding
- Fprotein heterodimerization activity
- Pangiotensin-activated signaling pathway
- Pblood vessel diameter maintenance
- Pcalcium-mediated signaling
- Pcell chemotaxis
- PG protein-coupled receptor signaling pathway
- Pinflammatory response
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Lipid & lipoprotein metabolism
- ·low-density lipoprotein particle remodeling
- ·positive regulation of cholesterol metabolic process
Cell proliferation & survival
- ·regulation of cell population proliferation
Cell migration
- ·cell chemotaxis
Immune signalling
- ·inflammatory response
- ·positive regulation of inflammatory response
- ·regulation of inflammatory response
G protein-coupled signalling
- ·G protein-coupled receptor signaling pathway
- ·phospholipase C-activating G protein-coupled receptor signaling pathway
View underlying pathways (4)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Broader indication categories (1)Hide
Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.
22 medicines meet Open Targets' target-level approved-medicine definition; the 4 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Type-1 angiotensin II receptor antagonist
Indicated for Diabetes Mellitus, Heart Failure, Hypertension, Myocardial Infarction
Type-1 angiotensin II receptor antagonist
Type-1 angiotensin II receptor antagonist
Indicated for Diabetes Mellitus, Hypertension, Myocardial Infarction, Stroke
Type-1 angiotensin II receptor antagonist
Indicated for Diabetes Mellitus, Type 2, Diabetic Nephropathies, Hypertension, Kidney Failure, Chronic
Type-1 angiotensin II receptor antagonist
Indicated for Glomerulonephritis, IGA
Type-1 angiotensin II receptor antagonist
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene AGTR1
Gene-level evidence surfaced through the gene AGTR1 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
24 compounds recorded · 22 approved · 2 in clinical development
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (10)Hide
Raw Open Targets tractability assessment buckets, by modality.
Safety-related annotations
Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 4 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Regulatory approval
Approval: VALSARTAN (ANDA205357)
- Regulatory approval
Approval: SACUBITRIL AND VALSARTAN (ANDA219946)
- Product recall
Recall (Class II): VALSARTAN
- Label change
Label change: IRBESARTAN (NDA020757)
- Label change
Label change: IRBESARTAN (ANDA077205)
- Label change
Label change: IRBESARTAN (NDA020757)
- New publicationCardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF.
- Regulatory approval
Approval: Filspari (EMA)
- New publicationMulticenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
- New publicationAngiotensin-neprilysin inhibition versus enalapril in heart failure.
- New publicationIrbesartan in patients with heart failure and preserved ejection fraction.
- Regulatory approval
Approval: Aprovel (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.